Menu Close

Trending

Bayer bails on $670m CAR-T partnership with Atara
Sidekick and Pfizer prep launch of DTx for atopic dermatitis
Coalition aims to improve cancer drug access in poorer nations
Conducting successful commercial research in a primary care setting
EU imposes Horizon funding block on UK scientists

Byooviz

abstract eye

Market Access/ News/ News

FDA OKs first biosimilar of Roche’s blockbuster AMD drug Lucentis

, , , , , , , 0 Comment

Samsung Bioepis and Biogen have claimed the first FDA approval for a biosimilar version of Roche and Novartis’

X
FDA OKs first biosimilar of Roche’s blockbuster AMD drug Lucentis
https://pharmaphorum.com/news/fda-oks-first-biosimilar-of-roches-blockbuster-amd-drug-lucentis/
Samsung Bioepis HQ

News/ News/ Sales and Marketing

Europe has its first Lucentis biosimilar, Samsung Bioepis’ Byooviz

, , , , , , , 0 Comment

Novartis and Roche’s big-selling eye drug Lucentis has its first biosimilar competitor in Europe, after the European Commission

X
Europe has its first Lucentis biosimilar, Samsung Bioepis’ Byooviz
https://pharmaphorum.com/news/europe-has-its-first-lucentis-biosimilar-samsung-bioepis-byooviz/

Login

CONTINUE TO SITE >
X
Close in 10 seconds